Transgene Management
Management criteria checks 2/4
Transgene's CEO is Alessandro Riva, appointed in Jun 2023, has a tenure of 2.58 years. total yearly compensation is €840.00K, comprised of 71.4% salary and 28.6% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth $102.59K. The average tenure of the management team and the board of directors is 1.8 years and 5 years respectively.
Key information
Alessandro Riva
Chief executive officer
€840.0k
Total compensation
| CEO salary percentage | 71.43% |
| CEO tenure | 2.6yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.8yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -€37m |
| Mar 31 2025 | n/a | n/a | -€35m |
| Dec 31 2024 | €840k | €600k | -€34m |
| Sep 30 2024 | n/a | n/a | -€28m |
| Jun 30 2024 | n/a | n/a | -€23m |
| Mar 31 2024 | n/a | n/a | -€23m |
| Dec 31 2023 | €510k | €350k | -€22m |
| Sep 30 2023 | n/a | n/a | -€28m |
| Jun 30 2023 | n/a | n/a | -€33m |
| Mar 31 2023 | n/a | n/a | -€33m |
| Dec 31 2022 | €304k | n/a | -€33m |
Compensation vs Market: Alessandro's total compensation ($USD974.59K) is below average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Alessandro's compensation has increased whilst the company is unprofitable.
CEO
Alessandro Riva (65 yo)
Dr. Alessandro Riva, M.D., serves as a Director at Bicycle Therapeutics plc since March 25, 2025. He serves as Chairman of the Board and Chief Executive Officer of Transgene SA since June 1, 2023. He serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 2.6yrs | €840.00k | 0.034% $ 102.6k | |
| VP, Chief Quality Officer & Qualified Pharmacist | less than a year | €183.00k | no data | |
| VP & Chief Financial Officer | 1.8yrs | no data | no data | |
| Chief Technical Officer | less than a year | no data | no data | |
| Vice President & Chief Scientific Officer | 1.3yrs | no data | no data | |
| VP, General Counsel & Corporate Secretary | 9.8yrs | no data | no data | |
| Chief Human Resources Officer | 1.8yrs | no data | no data | |
| VP & Chief Business Officer | 2yrs | no data | no data | |
| VP of Medical Affairs & Chief Medical Officer | 1.3yrs | no data | no data | |
| Head of Translational Medicine | no data | no data | no data | |
| VP & Director of Human Resources | no data | no data | no data |
Experienced Management: TRGN.F's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 3.7yrs | €840.00k | 0.034% $ 102.6k | |
| Director | 26yrs | €26.00k | 0.038% $ 113.5k | |
| Honorary Chairman | 6yrs | no data | 33.39% $ 100.8m | |
| Non-Independent Director | 12.6yrs | no data | no data | |
| Independent Director | 3.7yrs | €24.00k | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 8.6yrs | €48.00k | no data | |
| Independent Director | 2.7yrs | €45.00k | no data | |
| Independent Director | 8.6yrs | €74.00k | no data | |
| Director | 5yrs | no data | no data | |
| Director | 2yrs | no data | 0.000020% $ 60.4 |
Experienced Board: TRGN.F's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/17 18:14 |
| End of Day Share Price | 2025/12/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Transgene SA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |